The estimated Net Worth of Hongming Chen is at least $2.14 Миллион dollars as of 26 October 2021. Hongming Chen owns over 30,500 units of Kala Bio stock worth over $1,231,180 and over the last 7 years he sold KALA stock worth over $100,200. In addition, he makes $810,110 as Chief Scientific Officer at Kala Bio.
Sign up
Hongming Chen KALA stock SEC Form 4 insiders trading
Hongming has made over 7 trades of the Kala Bio stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 30,500 units of KALA stock worth $55,205 on 26 October 2021.
The largest trade he's ever made was exercising 47,000 units of Kala Bio stock on 25 February 2021 worth over $108,100. On average, Hongming trades about 9,698 units every 95 days since 2017. As of 26 October 2021 he still owns at least 204,515 units of Kala Bio stock.
You can see the complete history of Hongming Chen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Hongming Chen biography
Dr. Hongming Chen Ph.D. serves as Chief Scientific Officer of the Company. Prior to that, Dr. Chen served as our Executive Vice President of Research from October 2013 to October 2014 and our Vice President of Research from January 2010 to October 2013. Prior to joining us, Dr. Chen served as Director of Formulation Development at TransForm Pharmaceuticals Inc., or TransForm, from 2000 to January 2010. Before joining TransForm, Dr. Chen conducted vaccine delivery research and development at AstraZeneca plc from 1997 to 2000, and at Merck & Co., Inc. from 1996 to 1997. Dr. Chen is a member of the National Academy of Engineering, the College of Fellows of the American Institute for Medical and Biological Engineering and the College of Fellows of the Controlled Release Society. Dr. Chen received a B.S. in Chemical Engineering from The University of Texas at Austin in 1992 and both an M.S. and a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology.
What is the salary of Hongming Chen?
As the Chief Scientific Officer of Kala Bio, the total compensation of Hongming Chen at Kala Bio is $810,110. There are 6 executives at Kala Bio getting paid more, with Mark Iwicki having the highest compensation of $2,556,170.
How old is Hongming Chen?
Hongming Chen is 49, he's been the Chief Scientific Officer of Kala Bio since 2014. There are 10 older and 7 younger executives at Kala Bio. The oldest executive at Kala Bio Inc. is Dr. Kim Brazzell Ph.D., 68, who is the Head of R&D and Chief Medical Officer.
What's Hongming Chen's mailing address?
Hongming's mailing address filed with the SEC is C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 210, WATERTOWN, MA, 02472.
Insiders trading at Kala Bio
Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... и Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.
What does Kala Bio do?
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
What does Kala Bio's logo look like?
Complete history of Hongming Chen stock trades at Kala Bio
Kala Bio executives and stock owners
Kala Bio executives and other stock owners filed with the SEC include:
-
Mark Iwicki,
Chairman of the Board, President, Chief Executive Officer -
Todd Bazemore,
Chief Operating Officer -
Eric Trachtenberg,
Chief Compliance Officer, General Counsel, Secretary -
Kim Brazzell,
Chief Medical Officer -
Mark T. Iwicki,
Chairman & CEO -
Dr. Kim Brazzell Ph.D.,
Head of R&D and Chief Medical Officer -
Hongming Chen,
Chief Scientific Officer -
Todd Bazemore,
Pres & COO -
Andrew Koven,
Lead Independent Director -
Rajeev Shah,
Independent Director -
Gregory Perry,
Independent Director -
Robert Paull,
Independent Director -
Howard Rosen,
Independent Director -
Gregory Grunberg,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
Mary Reumuth,
Chief Financial Officer, Treasurer -
James Patnoe,
Sr. VP of Market Access, Commercial Operations & Pricing -
Vincent Kosewski,
Sr. VP of Manufacturing & Supply Chain Management -
Michele LaRussa,
Sr. VP of Regulatory Affairs & Quality Assurance -
Kathleen McCann Kline,
Sr. VP of Marketing -
Eric L. Trachtenberg,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Jill S. Steier,
Exec. Director of Investor Relations & Corp. Communications -
Mary Reumuth CPA, CPA,
CFO & Treasurer -
Dr. Justin Hanes Ph.D.,
Founder & Chair of the Scientific Advisory Board -
Capital Partners Ii, Llcenr...,
-
Harbor Master Investors (Ca...,
10% owner -
Associates, L.L.C.Caxton Co...,
-
Paulina Hill,
Director -
Advisors Llc Orbi Med Capit...,
-
Capital Management, L.P.Ra ...,
-
Robert I Tepper,
Director -
Robert Langer,
Director -
Advisors Llc Orbi Med Capit...,
-
Michele La Russa,
Sr. VP, Regulatory and Quality -
C. Daniel Myers,
-
Marjan Farid,
-
Capital Management, L.P.Ra ...,
-
Romulus K Brazzell,
SEE REMARKS -
Mark S. Blumenkranz,
-
Darius Kharabi,
CHIEF BUSINESS OFFICER